ADMA Biologics, Inc. — Rendiconto Finanziario Trimestrale (NASDAQ:ADMA) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 2.55 B
Employee 647
Founded 2004
CEO N/A
Website www.admabiologics.com
Headquarter Delaware, United States
FIGI BBG002NCK5M5
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

2.55 B Capitalizzazione di mercato

Rapporto prezzo/utili

30.4

Rapporto prezzo/fatturato

8.76

Notizie

TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication

NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

Is ADMA Poised for Margin Growth and Supply Expansion in 2026?

Adma Biologics (ADMA) Laps the Stock Market: Here's Why

ADMA Biologics: The Short Report Is The Noise, Not The Signal (NASDAQ:ADMA)

Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?

NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up

Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio

Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study

ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Upgrade)

Novartis Bolsters Immunology Pipeline With Excellergy Deal